Advances and applications of biosensors in pulmonary hypertension

被引：0

作者：

Zhi Liu ^{[1
]}

Zhuojun Bai ^{[2
]}

Xiang Chen ^{[3
]}

Yajie Chen ^{[3
]}

Zhu Chen ^{[1
]}

Li Wang ^{[1
]}

Yi He ^{[3
]}

Yuan Guo ^{[2
]}

机构：

[1] Graduate Collaborative Training Base of Zhuzhou Central Hospital, Hengyang Medical School, University of South China, Hunan, Hengyang

[2] Department of Cardiovascular Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, No. 116 South Changjiang Road, Hunan, Zhuzhou

[3] Department of Laboratory, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, No. 116 South Changjiang Road, Hunan, Zhuzhou

来源：

Respiratory Research | / 26卷 / 1期

关键词：

Biomarkers; Biosensors; Nanomaterials; Pulmonary hypertension;

D O I：

10.1186/s12931-025-03221-w

中图分类号：

学科分类号：

摘要：

Pulmonary hypertension (PH) is a serious disease characterized by elevated pulmonary artery pressure, with its prevalence and incidence continuously increasing, posing a threat to the lives of many patients worldwide. Due to the complex etiology of PH and the lack of specificity in clinical manifestations, there is currently a lack of effective and specific methods for early diagnosis in clinical practice. Biosensors hold significant promise for the early detection, therapeutic monitoring, prognostic evaluation, and personalized treatment of PH, owing to their rapid, sensitive, and highly selective characteristics. The rapid development of various types of biosensors, such as electrochemical biosensors, optical biosensors, microfluidic biosensors, and wireless biosensors, combined with the use of nanomaterials, makes the rapid and accurate detection of PH-related biomarkers possible. Despite the broad application prospects of biosensors in the field of PH, challenges remain in terms of sensitivity, selectivity, stability, and regulation. This article reviews the main pathophysiological mechanisms and commonly used biomarkers of PH, the types and principles of biosensors, and summarizes the progress of biosensors in PH research as well as the current challenges, in order to promote further in-depth research and the development of biosensor technology, thereby improving the diagnosis and treatment effects of PH. Clinical trial number: Not applicable. © The Author(s) 2025.

引用

共 133 条

[1] Maron B.A., Revised definition of pulmonary hypertension and approach to management: A clinical primer, J Am Heart Assoc, 12, 8, (2023)
[2] Mocumbi A., Humbert M., Saxena A., Jing Z.C., Sliwa K., Thienemann F., Et al., Pulmonary hypertension, Nat Rev Dis Primers, 10, 1, (2024)
[3] Vernekar P.R., Purohit B., Shetti N.P., Chandra P., Glucose modified carbon paste sensor in the presence of cationic surfactant for mefenamic acid detection in urine and pharmaceutical samples, Microchem J, 160, (2021)
[4] Baranwal A., Chiranjivi A.K., Kumar A., Dubey V.K., Chandra P., Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania Sci Rep, 8, 1, (2018)
[5] Uday Pratap Azad P.C., Handbook of nanobioelectrochemistry: application in devices and biomolecular sensing, (2023)
[6] Barreiros Dos Santos M., Rodriguez-Lorenzo L., Queiros R., Espina B., Fundamentals of biosensors and detection methods, Adv Exp Med Biol, 1379, pp. 3-29, (2022)
[7] Alhadrami H.A., Biosensors, Classifications, medical applications, and future prospective, Biotechnol Appl Biochem, 65, 3, pp. 497-508, (2018)
[8] Olejnik B., Koziol A., Brzozowska E., Ferens-Sieczkowska M., Application of selected biosensor techniques in clinical diagnostics, Expert Rev Mol Diagn, 21, 9, pp. 925-937, (2021)
[9] Purohit B., Kumar A., Mahato K., Roy S., 9 - C.P.C., Cancer cytosensing approaches in miniaturized settings based on advanced nanomaterials and biosensors, Nanotechnology in modern animal biotechnology, pp. 133-147, (2019)
[10] Singh N., Mullin C.J., Diagnosis of pulmonary hypertension, R I, Med J, 104, 7, pp. 30-35, (2013)

← 1 2 3 4 5 6 7 8 9 10 →